Correspondence 0001651308-25-000041 from BeOne Medicines Ltd. (BEIGF)
BeOne Medicines Ltd.
Date: March 6, 2025 · CIK: 0001651308 · Accession: 0001651308-25-000041
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-281324
Letter
Document
March 6, 2025
By EDGAR Submission
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F. Street, N.E.
Washington, D.C. 20549
Attention: Ms. Doris Stacey Gama and Mr. Chris Edwards
Re:
BeiGene, Ltd.
Acceleration Request for Registration Statement on Form S-4
File No. 333-281324
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), BeiGene, Ltd. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to March 7, 2025, at 4:05 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our outside counsel, Goodwin Procter LLP, by calling Edwin O’Connor at (212) 813-8853. We also respectfully request that a copy of the written order from the U.S. Securities and Exchange Commission verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Edwin O’Connor, by email to EOConnor@goodwinlaw.com or by facsimile to (212) 937-3476.
If you have any questions regarding this request, please contact Edwin O’Connor of Goodwin Procter LLP at (212) 813-8853.
***
Sincerely,
BeiGene, Ltd.
Show Raw Text
CORRESP 1 filename1.htm Document March 6, 2025 By EDGAR Submission U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. Street, N.E. Washington, D.C. 20549 Attention: Ms. Doris Stacey Gama and Mr. Chris Edwards Re: BeiGene, Ltd. Acceleration Request for Registration Statement on Form S-4 File No. 333-281324 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), BeiGene, Ltd. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to March 7, 2025, at 4:05 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our outside counsel, Goodwin Procter LLP, by calling Edwin O’Connor at (212) 813-8853. We also respectfully request that a copy of the written order from the U.S. Securities and Exchange Commission verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Edwin O’Connor, by email to EOConnor@goodwinlaw.com or by facsimile to (212) 937-3476. If you have any questions regarding this request, please contact Edwin O’Connor of Goodwin Procter LLP at (212) 813-8853. *** Sincerely, BeiGene, Ltd. /s/ Chan Lee Chan Lee Senior Vice President, General Counsel Enclosures cc: Aaron Rosenberg, Chief Financial Officer, BeiGene, Ltd. Qing Nian, Head of Legal North America & Corporate, BeiGene, Ltd. Edwin O’Connor, Goodwin Procter LLP Marishka DeToy, Goodwin Procter LLP Folake Ayoola, Goodwin Procter LLP